Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC

被引:33
作者
Ma, Xinran [1 ]
Bellomo, Lawrence [1 ]
Magee, Kelly [1 ]
Bennette, Caroline S. [1 ]
Tymejczyk, Olga [1 ]
Samant, Meghna [1 ]
Tucker, Melisa [1 ]
Nussbaum, Nathan [1 ,2 ]
Bowser, Bryan E. [1 ]
Kraut, Joshua S. [1 ]
Bourla, Ariel Bulua [1 ]
机构
[1] Flatiron Hlth Inc, New York, NY 10013 USA
[2] NYU, Sch Med, New York, NY USA
关键词
Real-world data; Real-world evidence; RECIST; Response; RWD; RWE; CELL LUNG-CANCER; OPEN-LABEL; DOCETAXEL; PEMBROLIZUMAB; CHEMOTHERAPY; NIVOLUMAB; SURVIVAL;
D O I
10.1007/s12325-021-01659-0
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction Effectiveness metrics for real-word research, analogous to clinical trial ones, are needed. This study aimed to develop a real-world response (rwR) variable applicable to solid tumors and to evaluate its clinical relevance and meaningfulness. Methods This retrospective study used patient cohorts with advanced non-small cell lung cancer from a nationwide, de-identified electronic health record (EHR)-derived database. Disease burden information abstracted manually was classified into response categories anchored to discrete therapy lines (per patient-line). In part 1, we quantified the feasibility and reliability of data capture, and estimated the association between rwR status and real-world progression-free survival (rwPFS) and real-world overall survival (rwOS). In part 2, we investigated the correlation between published clinical trial overall response rates (ORRs) and real-world response rates (rwRRs) from corresponding real-world patient cohorts. Results In part 1, 85.4% of patients (N = 3248) had at least one radiographic assessment documented. Median abstraction time per patient-line was 15.0 min (IQR 7.8-28.1). Inter-abstractor agreement on presence/absence of at least one assessment was 0.94 (95% CI 0.92-0.96; n = 503 patient-lines abstracted in duplicate); inter-abstractor agreement on best confirmed response category was 0.82 (95% CI 0.78-0.86; n = 384 with at least one captured assessment). Confirmed responders at a 3-month landmark showed significantly lower risk of death and progression in rwOS and rwPFS analyses across all line settings. In part 2, rwRRs (from 12 rw cohorts) showed a high correlation with trial ORRs (Spearman's rho = 0.99). Conclusions We developed a rwR variable generated from clinician assessments documented in EHRs following radiographic evaluations. This variable provides clinically meaningful information and may provide a real-world measure of treatment effectiveness.
引用
收藏
页码:1843 / 1859
页数:17
相关论文
共 39 条
[1]  
Akerley W., 2000, LUNG CANCER, V29, P33, DOI [10.1016/S0169-5002(00)80106-3, DOI 10.1016/S0169-5002(00)80106-3]
[2]  
[Anonymous], 2009, Pub. L
[3]  
[Anonymous], 2018, GUID IND BIOAN METH, P1
[4]   Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade [J].
Arbour, Kathryn C. ;
Luu, Anh Tuan ;
Luo, Jia ;
Rizvi, Hira ;
Plodkowski, Andrew J. ;
Sakhi, Mustafa ;
Huang, Kevin B. ;
Digumarthy, Subba R. ;
Ginsberg, Michelle S. ;
Girshman, Jeffrey ;
Kris, Mark G. ;
Riely, Gregory J. ;
Yala, Adam ;
Gainor, Justin F. ;
Barzilay, Regina ;
Hellmann, Matthew D. .
CANCER DISCOVERY, 2021, 11 (01) :59-67
[5]   Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer [J].
Bartlett, Cynthia Huang ;
Mardekian, Jack ;
Cotter, Matthew James ;
Huang, Xin ;
Zhang, Zhe ;
Parrinello, Christina M. ;
Bourla, Ariel Bulua .
PLOS ONE, 2020, 15 (04)
[6]   Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses [J].
Blumenthal, Gideon M. ;
Karuri, Stella W. ;
Zhang, Hui ;
Zhang, Lijun ;
Khozin, Sean ;
Kazandjian, Dickran ;
Tang, Shenghui ;
Sridhara, Rajeshwari ;
Keegan, Patricia ;
Pazdur, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :1008-+
[7]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[8]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[9]   FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019 [J].
Chen, Emerson Y. ;
Haslam, Alyson ;
Prasad, Vinay .
JAMA INTERNAL MEDICINE, 2020, 180 (06) :912-914
[10]   An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate [J].
Chen, Emerson Y. ;
Raghunathan, Vikram ;
Prasad, Vinay .
JAMA INTERNAL MEDICINE, 2019, 179 (07) :915-921